Regeneron Pharmaceuticals, Inc. $REGN Stock Holdings Trimmed by Harvey Capital Management Inc.

Harvey Capital Management Inc. lessened its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 50.1% in the second quarter, according to its most recent filing with the SEC. The firm owned 4,975 shares of the biopharmaceutical company’s stock after selling 5,001 shares during the quarter. Harvey Capital Management Inc.’s holdings in Regeneron Pharmaceuticals were worth $3,102,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently modified their holdings of the company. Insigneo Advisory Services LLC raised its stake in shares of Regeneron Pharmaceuticals by 3.0% during the fourth quarter. Insigneo Advisory Services LLC now owns 445 shares of the biopharmaceutical company’s stock valued at $343,000 after purchasing an additional 13 shares in the last quarter. Arjuna Capital grew its position in Regeneron Pharmaceuticals by 3.2% in the 1st quarter. Arjuna Capital now owns 457 shares of the biopharmaceutical company’s stock valued at $353,000 after buying an additional 14 shares in the last quarter. Guardian Wealth Advisors LLC NC grew its position in Regeneron Pharmaceuticals by 3.3% in the 4th quarter. Guardian Wealth Advisors LLC NC now owns 443 shares of the biopharmaceutical company’s stock valued at $342,000 after buying an additional 14 shares in the last quarter. TD Private Client Wealth LLC increased its stake in Regeneron Pharmaceuticals by 9.7% during the 4th quarter. TD Private Client Wealth LLC now owns 169 shares of the biopharmaceutical company’s stock valued at $130,000 after buying an additional 15 shares during the period. Finally, MCF Advisors LLC increased its stake in Regeneron Pharmaceuticals by 50.0% during the 4th quarter. MCF Advisors LLC now owns 45 shares of the biopharmaceutical company’s stock valued at $35,000 after buying an additional 15 shares during the period. Institutional investors own 83.31% of the company’s stock.

Insider Buying and Selling

In other Regeneron Pharmaceuticals news, Director Kathryn Guarini sold 400 shares of the company’s stock in a transaction on Monday, August 10th. The stock was sold at an average price of $800.00, for a total value of $320,000.00. Following the transaction, the director owned 603 shares of the company’s stock, valued at approximately $482,400. This represents a 39.88% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Huda Y. Zoghbi sold 800 shares of the stock in a transaction on Monday, August 10th. The shares were sold at an average price of $800.00, for a total value of $640,000.00. Following the sale, the director owned 1,703 shares of the company’s stock, valued at $1,362,400. This trade represents a 31.96% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 1,400 shares of company stock worth $1,090,030. Corporate insiders own 6.97% of the company’s stock.

Wall Street Analysts Forecast Growth

REGN has been the topic of a number of recent analyst reports. HSBC dropped their price target on shares of Regeneron Pharmaceuticals from $990.00 to $880.00 and set a “buy” rating on the stock in a research report on Monday, July 6th. Weiss Ratings reiterated a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a research note on Wednesday, June 24th. BMO Capital Markets lowered their price objective on shares of Regeneron Pharmaceuticals from $900.00 to $730.00 and set an “outperform” rating on the stock in a research note on Monday, May 18th. Leerink Partners boosted their target price on Regeneron Pharmaceuticals from $641.00 to $824.00 and gave the stock a “market perform” rating in a report on Monday, August 17th. Finally, Piper Sandler cut their target price on Regeneron Pharmaceuticals from $855.00 to $854.00 and set an “overweight” rating for the company in a research report on Thursday, July 9th. Fifteen research analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $800.36.

Regeneron Pharmaceuticals Price Performance

Shares of Regeneron Pharmaceuticals stock opened at $807.71 on Friday. Regeneron Pharmaceuticals, Inc. has a 52 week low of $541.00 and a 52 week high of $847.00. The company has a current ratio of 3.34, a quick ratio of 2.78 and a debt-to-equity ratio of 0.06. The stock has a market cap of $83.16 billion, a PE ratio of 19.96, a price-to-earnings-growth ratio of 1.39 and a beta of 0.22. The company’s 50-day moving average price is $713.83 and its two-hundred day moving average price is $717.85.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share for the quarter, beating the consensus estimate of $10.16 by $4.13. The company had revenue of $4.29 billion during the quarter, compared to analyst estimates of $3.82 billion. Regeneron Pharmaceuticals had a net margin of 27.86% and a return on equity of 13.47%. The business’s revenue for the quarter was up 16.7% on a year-over-year basis. During the same quarter last year, the firm posted $12.81 EPS. As a group, sell-side analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 44.25 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, August 31st. Investors of record on Tuesday, August 18th will be paid a dividend of $0.94 per share. The ex-dividend date of this dividend is Tuesday, August 18th. This represents a $3.76 annualized dividend and a yield of 0.5%. Regeneron Pharmaceuticals’s dividend payout ratio is currently 9.29%.

Key Stories Impacting Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: The FDA approved Pasatru (garetosmab) for adults with fibrodysplasia ossificans progressiva, an ultra-rare genetic disorder that causes abnormal bone formation and progressive loss of movement. Approval gives Regeneron a new commercial product and strengthens its rare-disease portfolio. However, the small patient population may limit its immediate contribution to earnings. Can Regeneron’s Rare-Disease Win Move the Earnings Needle?
• Neutral Sentiment: A Sound Shore Management investor letter highlighted Regeneron’s need to adjust its strategy following mixed results in melanoma drug trials. The commentary reflects ongoing investor debate about the company’s pipeline and long-term growth, while other market coverage indicates Wall Street remains reasonably constructive on the broader outlook. Regeneron Adjusts Course Amid Mixed Results in Melanoma Drug Trials
• Negative Sentiment: Multiple law firms announced or promoted a securities class action concerning allegations that Regeneron misled investors about the prospects of the Phase 3 Fianlimab-Libtayo trial for advanced melanoma. The trial failure reportedly caused a major selloff and an approximately $11 billion decline in market capitalization. The allegations have not been proven, but the litigation adds reputational, legal, and disclosure risk; the lead-plaintiff deadline is September 14, 2026. Regeneron Investors Have Opportunity to Lead Class Action Lawsuit

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.